Hypertension and low HDL cholesterol were associated with reduced kidney function across the age spectrum: A collaborative study

Annals of Epidemiology

Volumn 23, Issue 3, 2013, Pages 106-111

  Odden, Michelle C ^a   Tager, Ira B ^b   Gansevoort, Ron T ^c   Bakker, Stephan J L ^c   Fried, Linda F ^d   Newman, Anne B ^e   Katz, Ronit ^f   Satterfield, Suzanne ^g   Harris, Tamara B ^h   Sarnak, Mark J ⁱ   Siscovick, David ^f   Shlipak, Michael G ^d,j  

^a OREGON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^h NATIONAL INSTITUTE ON AGING   (United States)

ⁱ TUFTS MEDICAL CENTER   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Aged; Cholesterol; Chronic kidney insufficiency; Hypertension; Obesity; Smoking

Indexed keywords

CYSTATIN C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; GROUPS BY AGE; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; SMOKING; SYSTOLIC BLOOD PRESSURE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; CAUSALITY; CHOLESTEROL, LDL; COHORT STUDIES; COMORBIDITY; CROSS-SECTIONAL STUDIES; CYSTATIN C; FEMALE; HUMANS; HYPERTENSION; KIDNEY FUNCTION TESTS; MALE; NETHERLANDS; OBESITY; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SMOKING; UNITED STATES;

EID: 84873473431     PISSN: 10472797     EISSN: 18732585     Source Type: Journal    
DOI: 10.1016/j.annepidem.2012.12.004     Document Type: Article

References (34)

1. Kronmal R.A., Cain K.C., Ye Z., Omenn G.S. Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. Arch Intern Med 1993, 153(9):1065-1073.
2. Satish S., Freeman D.H., Ray L., Goodwin J.S. The relationship between blood pressure and mortality in the oldest old. J Am Geriatr Soc 2001, 49(4):367-374.
3. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338:b1665.
4. Rimm E.B., Stampfer M.J., Giovannucci E., Ascherio A., Spiegelman D., Colditz G.A., et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol 1995, 141(12):1117-1127.
5. Seeman T., Mendes de Leon C., Berkman L., Ostfeld A. Risk factors for coronary heart disease among older men and women: a prospective study of community-dwelling elderly. Am J Epidemiol 1993, 138(12):1037-1049.
6. Briganti E.M., Branley P., Chadban S.J., Shaw J.E., McNeil J.J., Welborn T.A., et al. Smoking is associated with renal impairment and proteinuria in the normal population: the AusDiab kidney study. Australian Diabetes, Obesity and Lifestyle Study. Am J Kidney Dis 2002, 40(4):704-712.
7. Ejerblad E., Fored C.M., Lindblad P., Fryzek J., McLaughlin J.K., Nyren O. Obesity and risk for chronic renal failure. J Am Soc Nephrol 2006, 17(6):1695-1702.
8. Fox C.S., Larson M.G., Leip E.P., Culleton B., Wilson P.W., Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA 2004, 291(7):844-850.
9. Hunsicker L.G., Adler S., Caggiula A., England B.K., Greene T., Kusek J.W., et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997, 51(6):1908-1919.
10. Muntner P., Coresh J., Smith J.C., Eckfeldt J., Klag M.J. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000, 58(1):293-301.
11. Islam T.M., Fox C.S., Mann D., Muntner P. Age-related associations of hypertension and diabetes mellitus with chronic kidney disease. BMC Nephrol 2009, 10:17.
12. Dharnidharka V.R., Kwon C., Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002, 40(2):221-226.
13. Shlipak M.G., Praught M.L., Sarnak M.J. Update on cystatin C: new insights into the importance of mild kidney dysfunction. Curr Opin Nephrol Hypertens 2006, 15(3):270-275.
14. Fliser D., Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 2001, 37(1):79-83.
15. Hubbard A.E., Laan M.J. Population intervention models in causal inference. Biometrika 2008, 95(1):35-47.
16. Fried L.P., Borhani N.O., Enright P., Furberg C.D., Gardin J.M., Kronmal R.A., et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991, 1(3):263-276.
17. Bild D.E., Bluemke D.A., Burke G.L., Detrano R., Diez Roux A.V., Folsom A.R., et al. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol 2002, 156(9):871-881.
18. Gansevoort R.T., Verhave J.C., Hillege H.L., Burgerhof J.G., Bakker S.J., de Zeeuw D., et al. The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney Int Suppl 2005, (94):S28-S35.
19. Hillege H.L., Fidler V., Diercks G.F., van Gilst W.H., de Zeeuw D., van Veldhuisen D.J., et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002, 106(14):1777-1782.
20. Odden M.C., Tager I.B., Gansevoort R.T., Bakker S.J., Katz R., Fried L.F., et al. Age and cystatin C in healthy adults: a collaborative study. Nephrol Dial Transplant 2010, 25(2):463-469.
21. Erlandsen E.J., Randers E., Kristensen J.H. Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System. Scand J Clin Lab Invest 1999, 59(1):1-8.
22. Stevens L.A., Coresh J., Schmid C.H., Feldman H.I., Froissart M., Kusek J., et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008, 51(3):395-406.
23. Brantsma A.H., Bakker S.J., Hillege H.L., de Zeeuw D., de Jong P.E., Gansevoort R.T. Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. Diabetes Care 2005, 28(10):2525-2530.
24. Burnett R.W., D'Orazio P., Fogh-Andersen N., Kuwa K., Kulpmann W.R., Larsson L., et al. IFCC recommendation on reporting results for blood glucose. Clin Chim Acta 2001, 307(1-2):205-209.
25. van der Laan M.J., Gruber S. Collaborative double robust targeted maximum likelihood estimation. Int J Biostat 2010, 6(1). Article17.
26. Arnold B., Arana B., Mausezahl D., Hubbard A., Colford J.M. Evaluation of a pre-existing, 3-year household water treatment and handwashing intervention in rural Guatemala. Int J Epidemiol 2009, 38(6):1651-1661.
27. Gruber S., van der Laan M. Targeted maximum likelihood estimation: a gentle introduction. U.C. Berkeley Division of Biostatistics Working Paper Series 2009, Paper 252.
28. Sinisi S.E., van der Laan M.J. Deletion/substitution/addition algorithm in learning with applications in genomics. Stat Appl Genet Mol Biol 2004, 3. Article18.
29. Diamond J.R., Karnovsky M.J. Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int 1988, 33(5):917-924.
30. Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. Antiinflammatory properties of HDL. Circ Res 2004, 95(8):764-772.
31. Tonelli M., Isles C., Curhan G.C., Tonkin A., Pfeffer M.A., Shepherd J., et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004, 110(12):1557-1563.
32. Tonelli M., Moye L., Sacks F.M., Cole T., Curhan G.C. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003, 14(6):1605-1613.
33. Kendrick J., Shlipak M.G., Targher G., Cook T., Lindenfeld J., Chonchol M. Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. Am J Kidney Dis 2010, 55(1):42-49.
34. Flegal K.M., Williamson D.F., Graubard B.I. Using adjusted relative risks to calculate attributable fractions. Am J Public Health 2006, 96(3):398.